Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilofexor - Gilead Sciences/Phenex Pharmaceuticals

Next Previous
Drug Profile

Cilofexor - Gilead Sciences/Phenex Pharmaceuticals

Alternative Names: CILO; GS-9674; LBO-03

Latest Information Update: 16 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phenex Pharmaceuticals
  • Developer Gilead Sciences
  • Class Anti-inflammatories; Carboxylic acids; Hepatoprotectants; Nonsteroidal anti-inflammatories; Oxazoles; Pyridines; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Primary sclerosing cholangitis
  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • No development reported Primary biliary cirrhosis

Most Recent Events

  • 21 Jun 2023 Efficacy, adverse events and pharmacodynamics data from a phase III trial in Primary sclerosing cholangitis presented at the European Association for the Study of the Liver Congress (EASL-2023)
  • 20 Jan 2023 Gilead Sciences terminates phase III trial in Primary sclerosing cholangitis (In adults, In the elderly) in USA, Canada, Austria, United Kingdom, Switzerland, Spain, New Zealand, Japan, Italy, Italy, Israel, Germany, France, Finland, Denmark, Belgium and Australia (PO), owing to the low probability of achieving its primary end point (NCT03890120)
  • 04 Nov 2022 Pharmacodynamics data from a phase II ATLAS trial in Nonalcoholic steatohepatitis presented at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top